Reata's new CFO on M&A, weathering a recession and biotech's quirks

Manmeet Soni is on the move again.

The 41-year-old executive has already had several short, but successful, stints serving as chief financial officer of biotech companies, earning respect on Wall Street.  He was the CFO for Pharmacyclics when AbbVie paid $21 billion to acquire the Imbruvica developer in 2015. Less than a year after he started at Ariad Pharmaceuticals in the same role, Takeda paid $5.2 billion to buy that business.